One of the top performers in the last 6 months was the biotech small-cap Vidac Pharma, with a price increase of over 150%. Founded in 2012, the Company is led by Prof Max Herzberg, one of the founding fathers of the Israeli life sciences industry. Vidac Pharma is developing drugs that will help cancer patients by reversing the abnormal metabolism of cancer cells, thus stopping the proliferation of these cells. Despite its modest size, the Company is already in the clinical development phase.
News & Events